Luminex Corporation (LMNX) 22.79 $LMNX Luminex
Post# of 273254
Posted On: 09/24/2016 5:05:12 PM
Luminex Corporation (LMNX) 22.79 $LMNX
Luminex Poised on Pipeline Strength, System Sales Upbeat
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:19AM CDT
Austin-based Luminex (LMNX) is well poised on pipeline strength and solid system sales.
MASI: 59.77 (-0.55), QDEL: 22.71 (-0.08), LMNX: 22.79 (+0.04), NUVA: 66.77 (-1.29)
Luminex (LMNX) Receives FDA Clearance for xMAP Assay
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:24AM CDT
Luminex announced the receipt of Emergency Use Authorization (EUA) from FDA for the xMAP MultiFLEX Zika RNA Assay.
BAX: 47.49 (-0.71), QDEL: 22.71 (-0.08), LMNX: 22.79 (+0.04), NUVA: 66.77 (-1.29)
Luminex Corporation Receives FDA Emergency Use Authorization for Zika Virus Molecular Detection Assay
PR Newswire - Mon Aug 08, 7:30AM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen).
LMNX: 22.79 (+0.04)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.77 (-0.55), CPHD: 52.50 (unch), LMNX: 22.79 (+0.04), MLAB: 115.50 (-0.48)
Luminex Corporation Receives FDA Clearance for New Molecular Test for Identification and Differentiation of Influenza A/B and Respiratory Syncytial Virus
PR Newswire - Wed Aug 03, 7:30AM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Flu A/B & RSV Assay. This is the second assay the FDA has cleared for use on the Luminex ARIES® System.
LMNX: 22.79 (+0.04)
Luminex Corporation Reports Second Quarter 2016 Results
PR Newswire - Thu Jul 28, 3:05PM CDT
Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2016. Financial and operating highlights for the quarter include the following:
LMNX: 22.79 (+0.04)
Nanosphere Announces Intent to Voluntarily Delist From NASDAQ Capital Market
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it notified the NASDAQ Capital Market ("NASDAQ"
of its intent to file a Form 25 with the Securities and Exchange Commission on or about June 30, 2016, following the expiration of the Tender Offer (as defined below), to initiate the voluntary delisting of the Company's common stock (the "Common Stock" from NASDAQ in anticipation of the closing of the merger of Commodore Acquisition, Inc. ("Merger Sub", a wholly owned subsidiary of Luminex Corporation, with and into Nanosphere, on or about June 30, 2016. The official delisting of the Securities will be effective ten days after Nanosphere files the Form 25.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Increased Earnings Estimates Seen for Luminex (LMNX): Can It Move Higher?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:47AM CDT
Luminex (LMNX) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
LMNX: 22.79 (+0.04)
Luminex's ARIES Flu A/B & RSV Assay Now CE-IVD Marked
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:04AM CDT
Luminex Corp (LMNX) recently announced the receipt of CE-IVD marking for the ARIES Flu A/B & RSV Assay.
MASI: 59.77 (-0.55), EW: 119.77 (-1.10), LMNX: 22.79 (+0.04), CRY: 18.14 (-0.42)
Luminex Corporation Announces Commencement of Tender Offer for All Outstanding Shares of Nanosphere, Inc. Common Stock
PR Newswire - Thu Jun 02, 5:00AM CDT
Luminex Corporation (NASDAQ: LMNX) announced today that its wholly-owned subsidiary Commodore Acquisition, Inc. has commenced its previously announced tender offer to purchase all outstanding shares of common stock of Nanosphere, Inc. (NASDAQ: NSPH) for $1.70 per share in cash. The tender offer is being made pursuant to the Agreement and Plan of Merger entered into and among Luminex, Commodore, and Nanosphere dated May 15, 2016 as subsequently amended.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex Corporation Receives CE-IVD Mark for ARIES Flu A/B & RSV Assay
PR Newswire Europe - Wed Jun 01, 8:16AM CDT
Luminex Corporation today announced that it has received CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices for the ARIES((R)) Flu A/B & RSV Assay. Designed for use with the FDA cleared and CE-IVD marked ARIES((R)) System, the ARIES((R)) Flu A/B & RSV Assay is a rapid and accurate method for the detection and differentiation of three key respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) using a sample to answer platform.
LMNX: 22.79 (+0.04)
Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement
PR Newswire - Mon May 23, 5:00AM CDT
Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) announced today that they have entered into an amendment to the definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market. The purchase price has been increased to $1.70 per share from $1.35 per share in an all cash transaction valued at approximately $77 million. This increase was in response to an unsolicited third party offer for Nanosphere at $1.50 per share.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Nanosphere, Inc.
BusinessWire - Fri May 20, 5:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere" or "the Company" (Nasdaq: NSPH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Luminex Corporation ("Luminex".
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
NANOSPHERE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Nanosphere, Inc. (NSPH) Over the Proposed Sale of the Company to Luminex Corporation
BusinessWire - Fri May 20, 3:22PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Nanosphere, Inc. ("Nanosphere" or the "Company" (NASDAQ:NSPH) for potential breaches of fiduciary duties in connection with the sale of the Company to Luminex Corporation for approximately $58 million in an all-cash transaction.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Nanosphere, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Luminex Corporation
BusinessWire - Thu May 19, 1:34PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere" (NASDAQ: NSPH) concerning the merger with Luminex Corporation. Under the terms of the agreement, valued at approximately $58 million, Nanosphere shareholders will only receive $1.35 per share held. The consideration is significantly lower than at least one analyst's estimated value of $1.65.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Nanosphere, Inc. -NSPH
PR Newswire - Wed May 18, 7:49PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere" or "the Company" (Nasdaq: NSPH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Luminex Corporation ("Luminex".
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex (LMNX) to Buy Nanosphere, Eyes Portfolio Expansion
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:02AM CDT
Luminex Corp (LMNX) is set to acquire IL-based biotech company Nanosphere (NSPH) for almost $58 million ($1.35 per share) in cash.
IRMD: 17.29 (-0.51), EW: 119.77 (-1.10), LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex to Highlight Latest Additions to Product Portfolio at the 2016 Clinical Virology Symposium
PR Newswire - Mon May 16, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) today announced it will highlight the latest additions to its product portfolio at the 32nd Annual Clinical Virology Symposium, a meeting of the American Society for Microbiology, taking place May 19-21 in Daytona Beach, Florida. The new ARIES® System will be featured in seven poster presentations, and showcased in a company-sponsored workshop. The recently FDA-cleared and CE-marked NxTAG® Respiratory Pathogen Panel (RPP) will be featured in eight posters. More information, including a select list of Luminex-related posters and events, is available online.
LMNX: 22.79 (+0.04)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Nanosphere, Inc. to Luminex Corporation for $1.35 Per Share - NSPH
ACCESSWIRE - Mon May 16, 10:03AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex Poised on Pipeline Strength, System Sales Upbeat
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:19AM CDT
Austin-based Luminex (LMNX) is well poised on pipeline strength and solid system sales.
MASI: 59.77 (-0.55), QDEL: 22.71 (-0.08), LMNX: 22.79 (+0.04), NUVA: 66.77 (-1.29)
Luminex (LMNX) Receives FDA Clearance for xMAP Assay
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:24AM CDT
Luminex announced the receipt of Emergency Use Authorization (EUA) from FDA for the xMAP MultiFLEX Zika RNA Assay.
BAX: 47.49 (-0.71), QDEL: 22.71 (-0.08), LMNX: 22.79 (+0.04), NUVA: 66.77 (-1.29)
Luminex Corporation Receives FDA Emergency Use Authorization for Zika Virus Molecular Detection Assay
PR Newswire - Mon Aug 08, 7:30AM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen).
LMNX: 22.79 (+0.04)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.77 (-0.55), CPHD: 52.50 (unch), LMNX: 22.79 (+0.04), MLAB: 115.50 (-0.48)
Luminex Corporation Receives FDA Clearance for New Molecular Test for Identification and Differentiation of Influenza A/B and Respiratory Syncytial Virus
PR Newswire - Wed Aug 03, 7:30AM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Flu A/B & RSV Assay. This is the second assay the FDA has cleared for use on the Luminex ARIES® System.
LMNX: 22.79 (+0.04)
Luminex Corporation Reports Second Quarter 2016 Results
PR Newswire - Thu Jul 28, 3:05PM CDT
Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2016. Financial and operating highlights for the quarter include the following:
LMNX: 22.79 (+0.04)
Nanosphere Announces Intent to Voluntarily Delist From NASDAQ Capital Market
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it notified the NASDAQ Capital Market ("NASDAQ"
of its intent to file a Form 25 with the Securities and Exchange Commission on or about June 30, 2016, following the expiration of the Tender Offer (as defined below), to initiate the voluntary delisting of the Company's common stock (the "Common Stock" from NASDAQ in anticipation of the closing of the merger of Commodore Acquisition, Inc. ("Merger Sub", a wholly owned subsidiary of Luminex Corporation, with and into Nanosphere, on or about June 30, 2016. The official delisting of the Securities will be effective ten days after Nanosphere files the Form 25. LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Increased Earnings Estimates Seen for Luminex (LMNX): Can It Move Higher?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:47AM CDT
Luminex (LMNX) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
LMNX: 22.79 (+0.04)
Luminex's ARIES Flu A/B & RSV Assay Now CE-IVD Marked
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:04AM CDT
Luminex Corp (LMNX) recently announced the receipt of CE-IVD marking for the ARIES Flu A/B & RSV Assay.
MASI: 59.77 (-0.55), EW: 119.77 (-1.10), LMNX: 22.79 (+0.04), CRY: 18.14 (-0.42)
Luminex Corporation Announces Commencement of Tender Offer for All Outstanding Shares of Nanosphere, Inc. Common Stock
PR Newswire - Thu Jun 02, 5:00AM CDT
Luminex Corporation (NASDAQ: LMNX) announced today that its wholly-owned subsidiary Commodore Acquisition, Inc. has commenced its previously announced tender offer to purchase all outstanding shares of common stock of Nanosphere, Inc. (NASDAQ: NSPH) for $1.70 per share in cash. The tender offer is being made pursuant to the Agreement and Plan of Merger entered into and among Luminex, Commodore, and Nanosphere dated May 15, 2016 as subsequently amended.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex Corporation Receives CE-IVD Mark for ARIES Flu A/B & RSV Assay
PR Newswire Europe - Wed Jun 01, 8:16AM CDT
Luminex Corporation today announced that it has received CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices for the ARIES((R)) Flu A/B & RSV Assay. Designed for use with the FDA cleared and CE-IVD marked ARIES((R)) System, the ARIES((R)) Flu A/B & RSV Assay is a rapid and accurate method for the detection and differentiation of three key respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) using a sample to answer platform.
LMNX: 22.79 (+0.04)
Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement
PR Newswire - Mon May 23, 5:00AM CDT
Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) announced today that they have entered into an amendment to the definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market. The purchase price has been increased to $1.70 per share from $1.35 per share in an all cash transaction valued at approximately $77 million. This increase was in response to an unsolicited third party offer for Nanosphere at $1.50 per share.
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Nanosphere, Inc.
BusinessWire - Fri May 20, 5:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere" or "the Company"
(Nasdaq: NSPH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Luminex Corporation ("Luminex". LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
NANOSPHERE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Nanosphere, Inc. (NSPH) Over the Proposed Sale of the Company to Luminex Corporation
BusinessWire - Fri May 20, 3:22PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Nanosphere, Inc. ("Nanosphere" or the "Company"
(NASDAQ:NSPH) for potential breaches of fiduciary duties in connection with the sale of the Company to Luminex Corporation for approximately $58 million in an all-cash transaction. LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Nanosphere, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Luminex Corporation
BusinessWire - Thu May 19, 1:34PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere"
(NASDAQ: NSPH) concerning the merger with Luminex Corporation. Under the terms of the agreement, valued at approximately $58 million, Nanosphere shareholders will only receive $1.35 per share held. The consideration is significantly lower than at least one analyst's estimated value of $1.65. LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Nanosphere, Inc. -NSPH
PR Newswire - Wed May 18, 7:49PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Nanosphere, Inc. ("Nanosphere" or "the Company"
(Nasdaq: NSPH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Luminex Corporation ("Luminex". LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex (LMNX) to Buy Nanosphere, Eyes Portfolio Expansion
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:02AM CDT
Luminex Corp (LMNX) is set to acquire IL-based biotech company Nanosphere (NSPH) for almost $58 million ($1.35 per share) in cash.
IRMD: 17.29 (-0.51), EW: 119.77 (-1.10), LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
Luminex to Highlight Latest Additions to Product Portfolio at the 2016 Clinical Virology Symposium
PR Newswire - Mon May 16, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) today announced it will highlight the latest additions to its product portfolio at the 32nd Annual Clinical Virology Symposium, a meeting of the American Society for Microbiology, taking place May 19-21 in Daytona Beach, Florida. The new ARIES® System will be featured in seven poster presentations, and showcased in a company-sponsored workshop. The recently FDA-cleared and CE-marked NxTAG® Respiratory Pathogen Panel (RPP) will be featured in eight posters. More information, including a select list of Luminex-related posters and events, is available online.
LMNX: 22.79 (+0.04)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Nanosphere, Inc. to Luminex Corporation for $1.35 Per Share - NSPH
ACCESSWIRE - Mon May 16, 10:03AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
LMNX: 22.79 (+0.04), NSPH: 1.69 (-0.01)
(0)
(0)Scroll down for more posts ▼